CytRx Corporation (CYTR): Price and Financial Metrics


CytRx Corporation (CYTR): $0.09

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CYTR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CYTR Stock Price Chart Interactive Chart >

Price chart for CYTR

CYTR Price/Volume Stats

Current price $0.09 52-week high $0.86
Prev. close $0.09 52-week low $0.05
Day low $0.09 Volume 4,000
Day high $0.10 Avg. volume 99,706
50-day MA $0.10 Dividend yield N/A
200-day MA $0.25 Market Cap 4.14M

CytRx Corporation (CYTR) Company Bio


CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company was founded in 1985 and is based in Los Angeles, California.


CYTR Latest News Stream


Event/Time News Detail
Loading, please wait...

CYTR Latest Social Stream


Loading social stream, please wait...

View Full CYTR Social Stream

Latest CYTR News From Around the Web

Below are the latest news stories about CYTRX CORP that investors may wish to consider to help them evaluate CYTR as an investment opportunity.

LadRx Corporation Announces OTCQB Ticker Change to LADX

LOS ANGELES, October 05, 2022--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022.

Yahoo | October 5, 2022

CytRx Corporation Relaunches as LadRx Corporation

LOS ANGELES, September 23, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.

Yahoo | September 23, 2022

European Patent Office Awards CytRx Key Patent

LOS ANGELES, September 07, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has been awarded a key patent by the European Patent Office, and that the period for parties to oppose the patent has lapsed without opposition.

Yahoo | September 7, 2022

CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors

LOS ANGELES, August 09, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the "Board").

Yahoo | August 9, 2022

CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

LOS ANGELES, May 19, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 pm Eastern Time on May 20, 2022. The outstanding shares of

Yahoo | May 19, 2022

Read More 'CYTR' Stories Here

CYTR Price Returns

1-mo N/A
3-mo N/A
6-mo -5.16%
1-year -80.74%
3-year -87.05%
5-year -95.11%
YTD N/A
2022 0.00%
2021 -71.14%
2020 503.45%
2019 -35.56%
2018 -73.37%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7562 seconds.